FREE SHIPFree U.S. shipping on orders over $150Free U.S. shipping on orders over $150
Free U.S. shipping on orders over $150
Research-grade compound with certificate of analysis. Full analytical testing on every lot.
Tesamorelin, CJC-1295 No DAC, and ipamorelin are a combination of investigational peptides that engage complementary growth hormone–releasing hormone (GHRH) and ghrelin receptor (GHS) pathways to modulate endogenous growth hormone pulsatility.
Mechanistic studies support GHRH–GHS cross-talk, though direct clinical evaluation of this three-peptide combination remains limited.
Tesamorelin is a synthetic analog of growth hormone–releasing hormone (GHRH) consisting of 44 amino acids, designed to stimulate endogenous growth hormone (GH) secretion from the anterior pituitary.
By activating the GHRH receptor, tesamorelin promotes pulsatile GH release and downstream increases in insulin-like growth factor-1 (IGF-1), while preserving physiologic feedback regulation.
Tesamorelin has been studied in metabolic research contexts for its ability to metabolize fat while maintaining muscle mass, particularly in HIV patients [1].
CJC-1295 is a synthetic peptide analog of growth hormone–releasing hormone that retains the core bioactive sequence of native GHRH but lacks the drug affinity complex (DAC) modification.
As a result, it has a shorter functional half-life and more closely mimics physiologic, pulsatile GH signaling rather than sustained elevation.
By binding to the GHRH receptor on pituitary somatotrophs, CJC-1295 without DAC stimulates endogenous growth hormone release and downstream IGF-1 production in a natural and feedback-regulated manner [2].
In research settings, it is often used as a tool to engage the GHRH axis without prolonged GH exposure.
Ipamorelin is a synthetic pentapeptide growth hormone secretagogue that selectively activates the ghrelin (GHS-R1a) receptor in the hypothalamus and pituitary.
Through this pathway, ipamorelin promotes pulsatile growth hormone release without significantly stimulating other pituitary hormones such as cortisol or prolactin [3].
In research models, ipamorelin is a commonly studied complement to GHRH analogs when examining coordinated regulation of the somatotropic axis.
This three-peptide combination is best understood as a multi-node strategy to engage the somatotropic axis.
Two components, tesamorelin and CJC-1295 No DAC, are GHRH-pathway agonists, while ipamorelin activates the ghrelin/GHS-R1a pathway, a distinct control system that can amplify GH release through complementary signaling.
Both tesamorelin and CJC-1295 without DAC stimulate the GHRH receptor on pituitary somatotrophs, via adenylyl cyclase activation and increased cAMP, supporting physiologic GH pulse generation when pituitary function is intact.
The most evidence-supported synergy in this stack comes from combining GHRH receptor activation (tesamorelin/CJC-1295 without DAC) with GHS-R1a activation (ipamorelin).
GHS compounds and ghrelin receptor agonism stimulate GH release via signaling that is typically described as PLC/second-messenger (Ca²⁺/DAG)–linked, distinct from the cAMP-centric GHRH pathway [4].
Controlled mechanistic studies show that co-activation of the GHRH receptor and the GHS receptor can amplify intracellular signaling beyond either pathway alone.
In a receptor-defined cell system expressing both receptors, activation of a GHS pathway (including ghrelin) potentiated the cAMP response to GHRH. The cAMP response approximately doubled compared with GHRH alone, suggesting receptor-level cross-talk that enhances somatotroph responsiveness [5].
This type of finding provides a strong rationale for pairing a GHRH analog with a selective GH secretagogue like ipamorelin when the goal is to model enhanced pulsatile GH dynamics rather than sustained GH elevation.
Aside from muscle anabolism, CJC-1295 combined with ipamorelin may also activate chondrocytes and osteoblast differentiation, suggesting potential use for cartilage and bone regeneration [6].
Direct studies evaluating tesamorelin + CJC-1295 No DAC + ipamorelin as a three-agent combination are not well represented in the peer-reviewed literature. What does exist is:
Given this, the most defensible conclusion is that the triple stack is mechanistically plausible, but not yet validated as a combined regimen in controlled clinical trials.
At a conceptual level, allocating more total mass to the GHRH-analog component (e.g., tesamorelin 6 mg alongside lower-dose CJC-1295 No DAC and ipamorelin) can be interpreted as emphasizing primary drive through the traditional GHRH pathway, with ipamorelin positioned as a complementary amplifier via GHS-R1a cross-talk.
Beyond that general framework, the optimal ratio is not established in public evidence and should be treated as an empirical design choice rather than a settled standard.
References:
1 Adrian, S., Scherzinger, A., Sanyal, A., Lake, J. E., Falutz, J., Dubé, M. P., et al. (2019) The growth hormone releasing hormone analogue, tesamorelin, decreases muscle fat and increases muscle area in adults with HIV. J. Frailty Aging, SERDI 8, 154–159
2 Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J.-P. and Frohman, L. A. (2006) Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J. Clin. Endocrinol. Metab. 91, 799–805
3 Raun, K., Hansen, B. S., Johansen, N. L., Thøgersen, H., Madsen, K., Ankersen, M., et al. (1998) Ipamorelin, the first selective growth hormone secretagogue. Eur. J. Endocrinol., Oxford University Press (OUP) 139, 552–561
4 Akalu, Y., Molla, M. D., Dessie, G. and Ayelign, B. (2020) Physiological effect of ghrelin on body systems. Int. J. Endocrinol., John Wiley & Sons, Ltd 2020, 1385138
5 Cunha, S. R. and Mayo, K. E. (2002) Ghrelin and growth hormone (GH) secretagogues potentiate GH-releasing hormone (GHRH)-induced cyclic adenosine 3’,5'-monophosphate production in cells expressing transfected GHRH and GH secretagogue receptors. Endocrinology, The Endocrine Society 143, 4570–4582
6 Rahman, O. F., Lee, S. J. and Seeds, W. A. (2026) Therapeutic peptides in orthopaedics: Applications, challenges, and future directions. J. Am. Acad. Orthop. Surg. Glob. Res. Rev., Ovid Technologies (Wolters Kluwer Health) 10, e25.00236
Every lot undergoes five independent assays before release. Results are published in the lot-specific Certificate of Analysis.
Every lot undergoes our 4-panel testing protocol: HPLC purity analysis, ESI-MS identity confirmation, LAL endotoxin screening, and amino acid analysis (for peptides >15 residues). Full analytical data is published in the Certificate of Analysis for each lot.
Lyophilized peptides should be stored at -20°C or below for long-term stability. Once reconstituted, peptides should be stored at 2–8°C and used within a reasonable timeframe depending on the specific compound. Avoid repeated freeze-thaw cycles. Always store in a dry environment away from direct light.
Orders placed before noon PST, Monday–Saturday, ship the same day. We offer free standard shipping on orders over $150. All orders are shipped in insulated packaging with ice packs when necessary. Standard delivery typically takes 2–4 business days within the continental US.
No. All compounds sold by Genesis Peptides are strictly for in vitro and preclinical laboratory research purposes only. They are not approved for human consumption, therapeutic use, or diagnostic purposes. By purchasing, you confirm the products will be used solely for legitimate research applications.
A Certificate of Analysis (COA) is a document issued by our analytical laboratory that reports the results of all quality control tests performed on a specific lot of product. Each COA includes HPLC chromatograms, mass spectra, endotoxin results, and amino acid analysis where applicable. COAs are available in our COA Library for every lot we have shipped.
Yes. We offer volume pricing for universities, research institutions, and laboratories with recurring needs. Discounts begin at 10+ units and scale with volume. Contact our team for a custom quote tailored to your research requirements.
Research Use Only. All findings described above are derived from preclinical studies (animal models and in vitro experiments). Tesamorelin + CJC-1295 (No DAC)+ Ipamorelin is not approved by the FDA for any diagnostic or therapeutic use in humans. Genesis Peptides makes no claims regarding human clinical efficacy. This product is sold exclusively for laboratory research.
FOR RESEARCH USE ONLY — Products are sold exclusively for in vitro and preclinical laboratory research. Not for human consumption or administration. Not intended for diagnostic or therapeutic use. These statements have not been evaluated by the FDA.
